Endometrial carcinoma where tumour testing detected microsatellite instability (MSI) or abnormal MMR immunohistochemistry
(except where there is loss of expression of MLH1, and hypermethylation of the MLH1 promoter)

Sarcoma of the endometrium (e.g. leiomyosarcoma) <60 years

For those with a personal history of cancer

Individual characteristics that warrant referral irrespective of other factors

Personal history of endometrial carcinoma and a second Lynch syndrome associated cancer

Personal history of endometrial carcinoma AND a family history of 1 or more 1st or 2nd degree relatives with colorectal or endometrial cancer, with at least one of the cancers diagnosed under the age of 50 years

Personal history of endometrial carcinoma AND a family history of 2 or more 1st or 2nd degree relatives with a Lynch syndrome-associated cancer regardless of the age the cancers were diagnosed

For those with a family history of cancer

Characteristics sufficient to warrant referral irrespective of other factors

Family history of 2 or more 1st or 2nd degree relatives with colorectal or endometrial cancer, with at least one of the cancers diagnosed under the age of 50 years

Family history of 3 or more 1st or 2nd degree relatives with a Lynch syndrome-associated cancer, regardless of the age the cancers were diagnosed

The information contained in this document is based on the highest level of available evidence and consensus of the eviQ reference committee regarding their views of currently accepted approaches to care or treatment. Any clinician seeking to apply or consult this document is expected to use independent clinical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use is subject to eviQ’s disclaimer available at www.eviQ.org.au